title: Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury.
abstract: Arterial injury by a balloon catheter produces marked smooth muscle cell proliferation and the participation of angiotensin II in this response has been suggested. In this study, we examined the effect of a novel angiotensin II type I receptor antagonist, TCV-116, on neointimal formation after rat carotid artery balloon injury. Oral administration of TCV-116 at doses of 1, 5 or 10 mg/kg/day significantly reduced the cross-sectional intimal area by 30%, 46% and 54%, respectively, and reduced the ratio of the intimal to medial cross-sectional areas by 23%, 41% and 50%. An angiotensin-converting enzyme inhibitor, lisinopril, had an effect similar to that of TCV-116. The effect of both drugs was significantly correlated with the reduction of both blood pressure and cardiac hypertrophy. We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy.
authors.affiliation: First Department of Internal Medicine, Kinki University School of Medicine, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kino
authors.forename: J
authors.initials: J
authors.lastname: Hama
authors.forename: T
authors.initials: T
authors.lastname: Takenaka
authors.forename: K
authors.initials: K
authors.lastname: Sugimura
authors.forename: K
authors.initials: K
authors.lastname: Kamoi
authors.forename: S
authors.initials: S
authors.lastname: Shimada
authors.forename: Y
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: S
authors.initials: S
authors.lastname: Nagata
authors.forename: M
authors.initials: M
authors.lastname: Horiuchi
authors.forename: R
authors.initials: R
authors.lastname: Katori
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002340:Carotid Artery Diseases / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D017536:Carotid Artery, Common / Q000187:drug effects / Q000473:pathology; D002404:Catheterization / Q000009:adverse effects*; D006973:Hypertension / Q000188:drug therapy; D017706:Lisinopril / Q000627:therapeutic use; D008297:Male; D011355:Prodrugs / Q000627:therapeutic use*; D051381:Rats; D011918:Rats, Inbred SHR; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011355:Prodrugs; D013777:Tetrazoles; D017706:Lisinopril; C077793:candesartan cilexetil